Clinical Trial: A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07629960) titled 'A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations' on June 01.

Brief Summary: A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor Non-Small Cell Lung Cancer Colorectal Neoplasms Pancreatic Ductal Adenocarcinoma

Intervention: DRUG: BLU-924

Tablet

Recruitment Status: RECRUITING

Spon...